IntroductIon A number of the recently published papers have suggested that high mortality among women with acute coronary syndromes might be related to suboptimal pharmaco logical treatment, namely to the lower rate of administration of antiplatelet agents, statins, β-blockers, and angiotensin-converting enzyme inhibitors (ACEIs).
IntroductIon For many years, both coronary artery disease (CAD) and acute coronary syndromes (ACS) were regarded as typically male diseases.
1 It appears to be an underestimated health problem among women. Only within the last 10 years, investigators have noticed that CAD is the most frequent cause of death also in women. 2, 3 In 2004, 55% of women and 43% of men died from cardiovascular disease in Europe.
4 Diagnostic difficulties and misconception about the small risk of developing heart disease in women may contribute to inadequate medical treatment in women with acute coronary syndrome.
1 Available evidence and data registries indicate that coronary revascularization and new antiplatelet drugs are significantly less
orIGInAL ArtIcLE
Pharmaco logical approach to patients with non-ST segment elevation myocardial infarction: does sex make a difference?
PAtIEnts And mEthods The records of 682 consecutive patients with NSTEMI admitted to hospitals in the Świętokrzyskie region between June 1, 2005 and May 31, 2006 were reviewed. There were 296 women (43.4%) and 386 men (56.6%). We analyzed in-hospital treatment and drugs prescribed at discharge. Permission was obtained to retrieve the data from PL-ACS. The study was approved by the Ethics Committee in the regional Chamber of Physicians (Świętokrzyska Izba Lekarska; No. 8/2007 rEsuLts Of all patients, 448 (65.7%) were admitted to the Świętokrzyskie Cardiology Center (Świętokrzyskie Centrum Kardio logii -ŚCK) in Kielce, and the remaining 234 (34.3%) to internal medicine wards in regional hospitals. During hospital stay, patients received ticlopidine, clopidogrel, and unfractionated heparin significantly more frequently in the ŚCK than elsewhere; however, acetylsalicylic acid (ASA) was used with similar frequency in all wards. The administration rate of low-molecular-weight heparin was higher in men in inter nal wards. The administration rate of thienopiridine derivatives and unfractionated heparin during the initial treatment in patients hospitalized in inter nal medicine wards was significantly lower than in those admitted to the reference center. A significantly lower administration rate of ACEIs in men and higher administration rate of nitrates in both sexes was observed in inter nal medicine wards. There were no significant frequently used in female patients. [5] [6] [7] [8] [9] In the recent decade, the European Society of Cardiology, including the Polish Cardiac Society as a member, has published 3 versions of its recommendations regarding treatment of non-ST-segment elevation myocardial infarction (NSTEMI) 5,10,11 and, additionally, recommendations regarding percutaneous revascularization, partly referring to NSTEMI. 12 In patients with NSTEMI, appropriate pharmacotherapy is of major importance. First of all, it maintains the favorable outcome of invasive treatment, but it has also been shown to prevent the development of new episodes, thus improving survival. In the acute phase, it is recommended to use antianginal, anticoagulant, and a combination of 2 antiplatelet drugs. Furthermore, each hospitalized patient without contraindications should receive β-adrenolytics, nitrates, heparin, or bivalirudine. 5 The cornerstone of long-term management are lifestyle changes, while fundamental pharmacotherapy includes 2 antiplatelet drugs, a β-adrenolytic agent and a statin. Moreover, subjects with type 2 diabetes, heart failure, and chronic renal insufficiency require angiotensin-converting enzyme inhibitors (ACEIs) and, if not tolerated, angiotensin-2 receptor blockers. 4 Most of the data regarding management of acute coronary syndrome were gathered from cardiology wards. The Polish Acute Coronary Syndrome Registry (PL-ACS) also included patients admitted to inter nal medicine wards, so it is possible to evaluate treatment offered in these wards as well. The present study was undertaken to compare pharmacotherapy in women treated for NSTEMI in inter nal medicine wards and a reference cardiology ward in the Świętokrzyskie region of Poland. Abbreviations: ACEIs -angiotensin-converting enzyme inhibitors, ASA -acetylsalicylic acid, LMWH -low-molecular-weight heparin, UFHunfractionated heparin the possible reasons for this discrepancy is that almost all high-risk patients were transferred to the PCI facility for invasive treatment, and those who remained in inter nal wards were treated medically with a very low rate of thienopyridine administration for secondary prevention.
The reasons for doing so are not clear. The most probable explanation is very poor adherence to the guidelines despite of their wide dissemination. 3 β-adrenolytics are given in 76% to 96% 3, 14, 16 of patients with a slight predominance of men.
16
These results were similar in our region. Surprisingly, contrary to previous reports, women in our study received β-blockers more frequently both on admission and at discharge, but the difference was not significant. Statins are used in 50% to 80% of patients, usually more frequently in men. 3, 13, 14, 16 In our group, the initial rate of statin administration was even better than in other observational studies. We suppose that a wide recommendation of β-block were more commonly used when a medical treatment was the method of choice. Registries indicate that drugs prescribed at discharge are similar to those used during hospitalization with a general tendency towards reduced amounts of ASA in favor of the remaining medications. 3, 16 In the Świętokrzyskie region, the use of specific medications does not differ much from the quoted proportions. However, some sex-and facility-related discrepancies, sometimes statistically significant, may be identified and call for an effort to improve the quality of care. Patients in the cardiology ward received thienopyridines more frequently, which was probably due to the fact that they were referred for coronary angiography. Contrary to the previous studies, a smaller percentage of patients received the recommended medications at discharge (i.e., antiplatelet agents), which might be associated with contraindications identified during hospitalization, such as bleeding complications (i.e., intracranial and gastrointestinal bleeding), 17 thrombocytopenia, ticlopidine intolerance, or referral for differences in the administration of other agents between male and female patients admitted to cardiology and other wards (tAbLE 1). Women and men discharged from inter nal medicine wards were prescribed ASA, clopidogrel, ACEIs, and statins (women additionally β-adrenolytics) significantly less frequently than those from the reference center. The proportion of patients receiving specific drugs was similar among women and men in general; however, in the reference center with percutaneous coronary inter vention (PCI) available, women were prescribed clopidogrel as a secondary prevention less frequently than men (tAbLE 2).
dIscussIon Sex-related discrepancies in the treatment of NSTEMI patients were widely researched in a large-scale observation from the CRUSADE Initiative by Blomkalns et al. 3 The main conclusion of this study is that the management of women with NSTEMI is far from ideal. However, the available evidence 13-15 shows a significant improvement in the mode of treatment of NSTEMI patients. Nevertheless, it appears that medical treatment of most European and American patients is suboptimal. The administration rate of the most popular agent, ASA, varies from 88% 3,16 to 98% 8,14 of patients and is similar in men and women. 3, 8, 16 In the present study, an initial ASA treatment rate was high regardless of the type of a facility; however, some significant differences between men and women appeared at discharge. Thienopyridine derivatives are most frequently administered in patients qualifying for percutaneous revascularization as a second antiplatelet drug preventing acute thrombosis. Thienopyridines are used less often, namely in 50% to 70% of men and in 33% to 50% of women. 3, [13] [14] [15] [16] They were used in 74.6% of women on admission to our reference center, which exceeds the rates reported elsewhere and appears to be satisfactory, but it is still much less than in men (84.9%). Initial treatment rate in internal wards was poor (about 36%-42%). One of a surgical treatment directly after coronary angiography. The numbers are especially small in inter nal medicine wards (tAbLE 2), which may be the result of a different patient distribution with predominantly elderly people having more contraindications to aggressive therapy. Although only some patients with acute coronary syndrome are optimally treated, progress is being made. 13, 14 Improvement in the quality of patient care is possible due to monitoring by means of patient registries and observational studies. 13-15 Special programs making physicians adhere to the guidelines are also valuable. 18 study limitations The retrospective nature of our analysis and the lack of possibility to modify the type of the collected data limited our assessment of certain issues. This pertains mainly to the lack of reasons for not administering some of the agents and to the lack of subanalyses of clinical characteristics of patients presenting at different facilities. That was the main reason why we did not assess the effect of pharmacotherapy on mortality.
conclusions The present findings suggest that there are no significant differences in pharmacotherapy between women and men with NSTEMI within a particular facility. In-hospital treatment in the reference center favored the use of anitiplatelet agents and unfractionated heparin in both sexes. The biggest concern is the reduced proportion of β-blockers, statins, and ACEIs prescribed in patients discharged from inter nal medicine wards.
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